Brompheniramine, phenylephrine (Dimetapp Cold And Allergy, Dimetapp Paediatric Cold & Allergy)
Brompheniramine, phenylephrine
Glaxosmithkline Consumer Healthcare SA (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Glaxosmithkline Consumer Healthcare SA (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Dimetapp cold and allergy EACH 5,0 ml LIQUID CONTAINS BROMPHENIRAMINE MALEATE 4,0 mg PHENYLEPHRINE HYDROCHLORIDE 10,0 mg | Not listed | 41003841/5.8/0038 | Cancelled | Not determined | None |
| Dimetapp paediatric cold & allergy EACH 5,0 ml LIQUID CONTAINS BROMPHENIRAMINE MALEATE 2,0 mg PHENYLEPHRINE HYDROCHLORIDE 5,0 mg | Not listed | 41099541/5.8/0995 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Phenylephrine
- when intended for injection
- except ophthalmic preparations containing 0,2 percent or less. (S0)
- except for oral dosage forms, nasal dosage forms, or ophthalmic dosage forms containing more than 0,2 percent (S1)
Consolidated Schedules 06 July 2026, lines 7545 to 7552
S2: Brompheniramine
Consolidated Schedules 06 July 2026, line 1692
S1: Phenylephrine
- when intended for oral dosage forms, nasal dosage forms, or ophthalmic dosage forms containing more than 0,2 percent; (S1)
- except ophthalmic preparations containing 0,2 percent or less; (S0)
- except when intended for injection. (S4)
Consolidated Schedules 06 July 2026, lines 1007 to 1014
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.